Core Viewpoint - The company, Maiwei Biotech, is focused on enhancing the quality and investment value of listed companies through its "Quality Improvement, Efficiency Enhancement, and Return to Investors" initiative, with significant progress in innovative drug development and commercialization strategies. Group 1: Innovative Drug Development - The company has 14 key products in various stages of development, including 10 innovative drugs and 4 biosimilars, primarily targeting oncology and age-related diseases [1][2] - Three clinical studies have advanced to Phase III, including treatments for urinary tract cancer and cervical cancer, with potential mid-analysis submissions for NDA expected in 2026 and 2027 [2][3] - The company is also developing a novel antibody-drug conjugate (ADC) targeting CDH17, which has shown promise in overcoming drug resistance in gastrointestinal cancers [2][3] Group 2: Commercialization and Sales Growth - In the first half of 2025, the company's drug sales revenue reached 100.79 million yuan, a 51.59% increase from the previous year [6][7] - The company has received necessary production licenses and is actively promoting new products, including its first innovative drug, which has optimistic market prospects [6][7] - A partnership with Qilu Pharmaceutical has been established to enhance the commercialization of long-acting white blood cell-boosting drugs [6][7] Group 3: Global Market Expansion - The company is pursuing international collaborations and has signed agreements with 30 countries for product registration and sales [8][9] - The company has successfully registered its products in Pakistan, marking a significant step in its global expansion strategy [8][9] - Ongoing negotiations with international pharmaceutical giants aim to broaden the company's product reach and enhance its market presence [9][10] Group 4: Production and Quality Management - The company has established production facilities compliant with international standards, enabling the commercial production of its drug candidates [11][12] - The production base has completed clinical trial sample preparations for 12 products and commercial production for 2 products as of June 30, 2025 [11][12] - The company is also expanding its production capacity to meet growing demands for its innovative drugs [12][13] Group 5: Corporate Governance and Investor Relations - The company emphasizes strong governance structures and internal controls to safeguard shareholder interests [14][15] - A commitment to enhancing information disclosure quality and investor communication has been established to foster transparency [16][17] - The company plans to repurchase shares to boost investor confidence and align interests among shareholders, employees, and the company [17][18]

证券代码：688062 证券简称：迈威生物 公告编号：2025-044 迈威（上海）生物科技股份有限公司 关于 2025 年半年度募集资金存放与 实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》的相关规定， 迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）董 事会就 2025 年半年度（以下简称"本报告期"）募集资金存放与实际使用情况 作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额及到账时间 根据中国证券监督管理委员会于 2021 年 12 月 7 日出具的《关于同意迈威 （上海）生物科技股份有限公司首次公开发行股票注册的批复》（证监许可 [2021]3859 号），公司获准向社会公开发行人民币普通股（A 股）99,900,000 股， 发行价格为每股人民币 34. ...

迈威（上海）生物科技股份有限公司 2025年度"提质增效重回报"行动方案 半年度评估报告 迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）为 响应上海证券交易所《关于向沪市公司发出开展"提质增效重回报"专项行动的 公开倡议》，倡议以"进一步提升上市公司质量和投资价值"为目标，引导上市公 司更好发挥主体责任，更好回报投资者，于 2025 年 3 月 30 日上海证券交易所网 站披露了《2025 年度"提质增效重回报"行动方案》。 2025 年上半年，公司根据行动方案内容积极开展和落实相关工作，现将 2025 年上半年"提质增效重回报"行动方案相关落实暨进展情况报告如下： 一、聚焦主营创新药研发，面向全球加快开发差异化创新药 公司自科创板上市以来，基于全产业链布局，始终围绕专注领域深度布局， 积极推进在研品种研发。目前公司拥有 14 个处于临床前、临床或上市阶段的重点 品种，包括 10 个创新药，4 个生物类似药，专注于肿瘤和年龄相关疾病，如免疫、 眼科、骨科等领域。其中，已上市品种 4 个，包括：迈利舒®（9MW0311，地舒 单抗注射液）、迈卫健®（9MW0321，地舒单抗注射液）、君迈康® ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-043 迈威（上海）生物科技股份有限公司 第二届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第十八次会议通知于 2025 年 8 月 19 日以书面方式送达全体监事，于 2025 年 8 月 29 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议应到 监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》等法 律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司章 程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2025年半年度报告>及摘要的议案》 经审议，全体监事认为公司编制的《2025 年半年度报告》及摘要符合相关 法律法规、中国证监会及上海证券交易所的有关规定，并真实反映了公司 2025 年半年度的实际经营情况。 表决结果：3 票同意，0 票反对，0 ...

公司代码：688062 公司简称：迈威生物 迈威（上海）生物科技股份有限公司 2025 年半年度报告 1 / 264 迈威（上海）生物科技股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 迈威（上海）生物科技股份有限公司 2025 年半年度报告 公司已于 2025 年 1 月向国家药品监督管理局药品审评中心提交了 9MW0813 的药品上市许可 申请前（pre-NDA）沟通交流会议申请，即将正式提交上市许可申请（NDA）。如上述品种未能 公司已在本报告中详细阐述公司核心竞争力风险、经营风险及行业风险等因素，敬请查阅本 报告第三节"管理层讨论与分析"之"四、风险因素"。并提请投资者特别关注如下风险： (一) 尚未盈利的风险 公司作为一家创新型生物医药企业，随着新药研发管线持续推进，多个创新药物处于关键临 床试验研究阶段，整体研发投入仍维持在较高水平。截至本报告披露日，公司拥有 14 个处于临床 前、临床或上市阶段的重点品种，包括 ...

Group 1 - The report highlights a shift in the macro narrative affecting the A-share market, driven by internal policies aimed at demand stimulation and external factors such as a weakening dollar [5][6]. - The report identifies a rotation in investment focus from TMT and manufacturing sectors to other areas, suggesting a potential shift in market dynamics [5][6]. - The report emphasizes the importance of high-low switching strategies in the technology sector, recommending stocks like Kunlun Wanwei, Leisai Intelligent, and Jingchen Co. for investment [5][10][14]. Group 2 - Kunlun Wanwei is focusing on AI business development, with significant advancements in AI chip research and application, leading to a positive outlook for its commercialization potential [10][11]. - Leisai Intelligent is expanding its market share in the automation sector, leveraging its strong product matrix and partnerships to capture growth opportunities [14][15]. - Jingchen Co. is experiencing robust growth in its AIoT and WiFi chip segments, with significant sales increases and a strong customer base [19][20]. Group 3 - Conch Cement is positioned to benefit from supply-side reforms and industry policy improvements, which are expected to enhance profitability and market conditions [24][25]. - Luzhou Laojiao is implementing proactive marketing strategies to adapt to market cycles, aiming to capture demand in emerging consumer segments [30][31]. - Jerry Holdings is poised for recovery as it capitalizes on the resurgence of high-end liquor demand and maintains a strong digital marketing framework [34][35]. Group 4 - New Hope Liuhe is leveraging its integrated supply chain advantages in the fine chemical sector, focusing on vitamin and amino acid production to enhance competitiveness [39][40]. - Xinhecheng is expected to benefit from rising prices in the vitamin market and increased demand for its amino acid products, supported by its strong production capabilities [39][41]. - Newnovel is projected to see significant revenue growth driven by its innovative drug pipeline, particularly in the oncology sector [43][44]. Group 5 - The report anticipates that the financial technology sector, represented by companies like Zhinan Zhen, will continue to grow as it transitions into comprehensive financial service providers [48][49]. - Zhinan Zhen's strategic acquisitions and capital operations are expected to enhance its market position and profitability in the coming years [48][50].

Group 1 - The A-share biopharmaceutical sector experienced a significant surge in the afternoon of August 29, with Rongchang Biopharmaceutical rising over 12% [2] - Maiwei Biopharmaceutical saw a sharp increase of 9% [2] - Kangchen Pharmaceutical previously hit the daily limit, while Sanofi and Wanzhe shares, as well as Sanyuan Gene, all rose over 6% [2]

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

Group 1 - The biopharmaceutical sector is experiencing active bidding, with notable stock performance including Tibet Pharmaceutical hitting the daily limit up, and Kangchen Pharmaceutical, Maiwei Biotech, and others opening higher [1] - Specific stock movements include Kangchen Pharmaceutical opening up by 5% and Maiwei Biotech also opening up by 4%, indicating positive market sentiment [1] - Other companies in the sector such as Rongchang Biotech, Hualan Vaccine, and Hualan Biotech also opened higher, reflecting a broader trend of optimism in the biopharmaceutical industry [1]

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Maiwei Biotechnology, indicating a significant increase in stock price and trading volume on August 27, with a 6.07% rise and a transaction amount of 1.116 billion yuan [1] - As of August 27, the financing balance of Maiwei Biotechnology reached 560 million yuan, representing 6.07% of its market capitalization, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - The company reported a revenue of 44.7885 million yuan for the first quarter of 2025, reflecting a year-on-year decrease of 33.70%, and a net profit attributable to shareholders of -292 million yuan, down 41.85% year-on-year [2] Group 2 - As of March 31, 2025, the number of shareholders of Maiwei Biotechnology increased by 4.22% to 16,100, while the average circulating shares per person decreased by 4.04% to 12,705 shares [2] - The top ten circulating shareholders include several funds, with HSBC Jintrust Smart Manufacturing Pioneer Stock A being the third largest shareholder, holding 4.705 million shares, a decrease of 136,200 shares from the previous period [2] - New entrants among the top ten shareholders include HSBC Jintrust Core Growth Mixed A and Innovation Drug, indicating a shift in institutional holdings [2]